Intermittent theta burst stimulation for negative symptoms of schizophrenia-A double-blind, sham-controlled pilot study.


Journal

NPJ schizophrenia
ISSN: 2334-265X
Titre abrégé: NPJ Schizophr
Pays: United States
ID NLM: 101657919

Informations de publication

Date de publication:
12 Feb 2021
Historique:
received: 19 08 2020
accepted: 22 12 2020
entrez: 13 2 2021
pubmed: 14 2 2021
medline: 14 2 2021
Statut: epublish

Résumé

Optimal noninvasive brain stimulation parameters for the treatment of negative symptoms of schizophrenia remain unclear. Here, we aimed to investigate the clinical and biological effects of intermittent theta burst transcranial magnetic stimulation (iTBS) in patients with treatment-resistant negative symptoms of schizophrenia (NCT00875498). In a randomized sham-controlled 2-arm study, 22 patients with schizophrenia and treatment-resistant negative symptoms received 20 sessions of either active (n = 12) or sham (n = 10) iTBS. Sessions were delivered twice a day on 10 consecutive working days. Negative symptom severity was assessed 5 times using the Scale for the Assessment of Negative Symptoms (SANS): before iTBS, after iTBS, and 1, 3, and 6 months after iTBS. As a secondary objective, we explored the acute effects of iTBS on functional connectivity of the left dorsolateral prefrontal cortex (DLPFC) using seed-based resting-state functional connectivity MRI (rsFC fMRI) images acquired before and after iTBS. Active iTBS over the left DLPFC significantly decreased negative symptoms severity compared to sham iTBS (F

Identifiants

pubmed: 33580032
doi: 10.1038/s41537-021-00138-3
pii: 10.1038/s41537-021-00138-3
pmc: PMC7880987
doi:

Types de publication

Journal Article

Langues

eng

Pagination

10

Références

Neuroscientist. 2013 Feb;19(1):43-61
pubmed: 22547530
Shanghai Arch Psychiatry. 2014 Feb;26(1):15-21
pubmed: 25114477
Br J Psychiatry Suppl. 1989 Nov;(7):49-58
pubmed: 2695141
World J Biol Psychiatry. 2020 Jul 27;:1-5
pubmed: 32657212
Hum Brain Mapp. 2018 Feb;39(2):783-802
pubmed: 29124791
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Am J Psychiatry. 2017 Mar 1;174(3):216-229
pubmed: 27919182
Neuroimage. 2017 Nov 15;162:289-296
pubmed: 28912081
Schizophr Bull. 2016 May;42(3):571-8
pubmed: 26564898
Schizophr Res. 2018 Jul;197:34-44
pubmed: 29397282
J Affect Disord. 2016 Aug;200:6-14
pubmed: 27107779
Schizophr Res. 2009 Jun;111(1-3):196-7
pubmed: 19339158
Schizophr Res. 2011 Sep;131(1-3):264-5
pubmed: 21669513
Psychol Med. 2015 Apr;45(6):1263-75
pubmed: 25354751
Pharmacopsychiatry. 2015 Mar;48(2):41-50
pubmed: 25584772
Psychiatry Res Neuroimaging. 2018 Jan 30;271:17-23
pubmed: 29220695
Neuropsychopharmacology. 2014 Mar;39(4):1020-30
pubmed: 24165885
Neuroimage. 2013 Sep;78:224-32
pubmed: 23567888
Schizophr Res. 1994 Feb;11(3):239-44
pubmed: 8193062
Psychiatry Res. 2014 Mar 30;215(3):505-13
pubmed: 24411074
Schizophr Bull. 2010 Sep;36(5):919-34
pubmed: 20566491
Neurophysiol Clin. 2010 Mar;40(1):27-36
pubmed: 20230933
Biol Psychiatry. 2015 Jun 1;77(11):979-88
pubmed: 25582269
Schizophr Res. 2013 Nov;150(2-3):328-33
pubmed: 24028744
World J Biol Psychiatry. 2018 Oct;19(7):497-508
pubmed: 28789578
Psychiatry Res. 2001 Nov 30;108(2):65-78
pubmed: 11738541
Clin Ther. 2011 Dec;33(12):B16-39
pubmed: 22177377
Clin Neurophysiol. 2020 Feb;131(2):474-528
pubmed: 31901449
Brain Stimul. 2020 May - Jun;13(3):840-849
pubmed: 32289715
Acta Psychiatr Scand Suppl. 1970;212:11-9
pubmed: 4917967
Am J Psychiatry. 2002 Feb;159(2):227-37
pubmed: 11823264
Neuron. 2005 Jan 20;45(2):201-6
pubmed: 15664172
Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):543-58
pubmed: 25797499
Psychiatry Res. 2016 Jun 30;240:333-335
pubmed: 27138827
Am J Psychiatry. 2013 Feb;170(2):165-72
pubmed: 23377637
Neuropsychobiology. 2012;66(1):24-32
pubmed: 22797274
J Neurosci. 2011 Jul 13;31(28):10340-6
pubmed: 21753011
Clin Neurophysiol. 2008 Jun;119(6):1393-9
pubmed: 18400556
Schizophr Bull. 2019 Sep 11;45(5):1051-1059
pubmed: 30576563
Psychol Med. 2018 Jan;48(1):82-94
pubmed: 28545597
Psychopharmacology (Berl). 2013 Jun;227(4):615-25
pubmed: 23455591
Schizophr Res. 2019 Jun;208:370-376
pubmed: 30704862
Arch Gen Psychiatry. 2000 May;57(5):471-80
pubmed: 10807487
Schizophr Bull. 2011 Mar;37(2):291-9
pubmed: 20861151
Ment Health Serv Res. 2004 Sep;6(3):185-8
pubmed: 15473104
Am J Psychiatry. 1995 Jun;152(6):876-82
pubmed: 7755117
J Neurosci. 2013 Apr 17;33(16):7050-6
pubmed: 23595762
Curr Top Behav Neurosci. 2016;27:375-410
pubmed: 26370946
Eur Psychiatry. 2018 Mar;49:69-77
pubmed: 29413808

Auteurs

Rémy Bation (R)

INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
University Lyon 1, Villeurbanne, France.
Centre Hospitalier Le Vinatier, Bron, France.
Psychiatry Unit, Wertheimer Hospital, CHU Lyon, Bron, France.

Charline Magnin (C)

INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
University Lyon 1, Villeurbanne, France.
Centre Hospitalier Le Vinatier, Bron, France.
Psychiatry Emergency Unit, Edouard Herriot Hospital, CHU Lyon, Lyon, France.

Emmanuel Poulet (E)

INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
University Lyon 1, Villeurbanne, France.
Centre Hospitalier Le Vinatier, Bron, France.
Psychiatry Emergency Unit, Edouard Herriot Hospital, CHU Lyon, Lyon, France.

Marine Mondino (M)

INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
University Lyon 1, Villeurbanne, France.
Centre Hospitalier Le Vinatier, Bron, France.

Jérôme Brunelin (J)

INSERM, U1028; CNRS, UMR5292; Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France. jerome.brunelin@ch-le-vinatier.fr.
University Lyon 1, Villeurbanne, France. jerome.brunelin@ch-le-vinatier.fr.
Centre Hospitalier Le Vinatier, Bron, France. jerome.brunelin@ch-le-vinatier.fr.

Classifications MeSH